[Federal Register Volume 65, Number 201 (Tuesday, October 17, 2000)]
[Notices]
[Pages 61340-61341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-26606]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committee for Pharmaceutical Science; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Advisory Committee for Pharmaceutical Science.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on November 15 and 16, 
2000, from 8:30 a.m. to 5:30 p.m.
    Location: University of Maryland, Shady Grove Campus, Auditorium, 
9640 Gudelsky Dr., Rockville, MD 20850.
    Contact Person: Nancy Chamberlin, Center for Drug Evaluation and 
Research (HFD 21), Food and Drug Administration, 5600 Fishers Lane (for 
express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 
301-827-7001, or e-mail: [email protected], or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12539. Please call the Information Line for 
up-to-date information on this meeting.
    Agenda: On November 15, 2000, the committee will: (1) Discuss 
approaches to reducing the regulatory burden for chemistry, 
manufacturing, and controls supplements; and (2) hear reports and 
provide direction to the Advisory Committee for Pharmaceutical 
Science's Subcommittee on Orally Inhaled and Nasal Drug Products, and 
to the Subcommittee on Nonclinical Studies. On November 16, 2000, the 
committee will: (1) Discuss the FDA guidance entitled ``A Guidance for 
Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies 
for Immediate-Release Solid Oral Dosage Forms Based on a 
Biopharmaceutics Classification System,'' see the FDA Internet web 
address www.fda.gov/cder/guidance/3618fnl.htm under the heading of 
``Biopharmaceutic Guidances;'' the FDA draft guidance entitled ``A 
Guidance for Industry, BA and BE Studies for Orally Administered Drug 
Products-General Considerations,'' see the FDA Internet

[[Page 61341]]

web address www.fda.gov/cder/guidance/2762dft.htm under the heading of 
``Biopharmaceutic Draft Guidances;'' and the FDA draft guidance 
entitled ``A Guidance for Industry, Average, Population, and Individual 
Approaches to Establishing Bioequivalence,'' see the FDA Internet web 
address www.fda.gov/cder/guidance/1716dft.htm under the heading of 
``Biopharmaceutic Draft Guidances;'' (2) provide comments and advice to 
the Clinical Pharmacology Modeling and Simulation Working Group; (3) 
receive updates on both FDA intramural research and the Product Quality 
Research Institute; and (4) provide advice on scientific issues 
specific to generic drugs.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by November 6, 
2000. Oral presentations from the public will be scheduled between 
approximately 1 p.m. to 2 p.m. Time allotted for each presentation may 
be limited. Those desiring to make formal oral presentations should 
notify the contact person before November 6, 2000, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: October 5, 2000.
Bernard A. Schwetz,
Acting Deputy Commissioner.
[FR Doc. 00-26606 Filed 10-16-00; 8:45 am]
BILLING CODE 4160-01-F